The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Conversion from radical esophagectomy to definitive chemoradiotherapy after neoadjuvant chemotherapy for advanced esophageal squamous cell carcinoma: Treatment options based on chemotherapy response.
 
Kiyoshi Narita
No Relationships to Disclose
 
Eiji Higaki
No Relationships to Disclose
 
Tetsuya Abe
No Relationships to Disclose
 
Hironori Fujieda
No Relationships to Disclose
 
Shingo Hashimoto
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Masahiro Tajika
Speakers' Bureau - Bristol-Myers Squibb Japan; Otsuka
Research Funding - Pfizer (Inst)
 
Takeshi Kodaira
No Relationships to Disclose
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Shimizu
No Relationships to Disclose